Bayer AI Imaging TechTalk: Speaking with Keya Medical
Mary Waiss, VP of Market Development at Keya Medical, and Michael Claytor, Senior Customer Success Manager at Bayer
DeepVessel analysis results-3D model and PDF report
Beyond accuracy, the noninvasive analysis fits seamlessly into everyday clinical practice. Clinicians receive an interactive 3D coronary model they can rotate, zoom, and click to see site-specific FFR values, alongside a concise PDF report highlighting key measurements. DeepVessel FFR delivers results fast, handles diverse image quality with low rejection rates, and only gets sharper as its training data grows.
On the business side, DeepVessel FFR carries Category I CPT code 75580, and Keya’s pricing is aligned with reimbursement to optimize patient access to this important technology. Paired with Bayer’s Calantic platform, which includes Bayer’s commitment to quality, curated sales support, and global reach, DVFFR is a turnkey solution that lowers costs, spares patients’ unnecessary procedures, and helps providers hit guideline-driven benchmarks.
Reimbursement – Category I CPT Code 75580
In 2025, CMS doubled hospital reimbursement for Coronary CTA (CCTA) by assigning it a higher Ambulatory Payment Classification (APC) and increased payments under the Physician Fee Schedule (PFS). As the recommended first-line test for suspected coronary artery disease (CAD), this update acknowledges CCTA’s value.
| Procedure | CY 2025 Final Rule |
| CCTA (APC 5572) | $357 |
| FFR CT (CPT 75580, APC 5724) | $1,017 |
| Procedure | CY 2025 Final Rule |
| CCTA (APC 5572) | $318 |
| FFT CT (75580 CPT, APC 5724) | $839 |
Q&A: Calantic AI Platform & DeepVessel FFR Analysis
- Q: What is DeepVessel FFR, and how does it relate to FFRCT?
- DeepVessel FFR (fractional flow reserve) is a non-invasive, AI-driven analysis of coronary CT angiography (CCTA) that quantifies the physiological severity of artery stenosis. It calculates a fractional flow reserve index—comparable to invasive FFR in the cath lab—using deep learning image processing on CCTA datasets.
- Q: Why should clinicians adopt DeepVessel FFR?
- Guideline Alignment: Recommended by AHA/ACC and SCCT as part of the optimal care pathway for patients with suspected coronary artery disease.
• Patient Triage: Enables functional assessment for lesions with 30–90% stenosis:
FFR > 0.80 → manage medically
FFR ≤ 0.80 → refer for invasive angiography
• Outcome Impact: Avoids >60% of unnecessary invasive procedures and reduces costs by ~30%.
- Q: What are the financial and operational benefits?
- Reimbursement: Assigned Category I CPT code 75580 (effective January 2024), which is aligned with the Medicare reimbursement.
- ROI: Neutral or positive revenue impact when pricing is aligned to reimbursement
- Time savings for clinical teams; more efficient allocation of cath lab resources.
- Q: What deliverables do clinicians receive?
- PDF Report: Summarizes vessel-specific FFR values in a clear table.
- Interactive 3D Model:
Rotatable, scalable coronary tree
Color coding (blue = patent; red = narrowed)
Click to display FFR at any point, aiding precise lesion evaluation
- Q: How does DeepVessel’s AI compare to computational flow dynamics (CFD)?
- Faster Turnaround: Deep learning inference vs. CFD simulations
- Improving Accuracy: Continuous performance gains as training datasets expand
- Lower Rejection Rates: Better handling of variable image quality
- Reduced Computational Power: Streamlined processing on standard hardware
- Q: Can DeepVessel FFR integrate with other Calantic AI applications?
- Yes. Seamless workflow enables radiologists to apply multiple AI tools on the same CCTA images, such as ScanSlated (patient-friendly report generators) and RAD AI (standardized interpretation assistants).
- Q: Why partner with Bayer’s Calantic AI orchestration platform
- Credibility & Trust: Association with a Fortune 100 healthcare leader accelerates market acceptance.
- Curated Ecosystem: Bayer selects the optimal product for each application on their platform.
- Sales & Marketing Support: Bayer trains and mobilizes its commercial team on Keya’s solution.
- Expanded Reach: Access to Bayer’s installed base and collaborative marketing amplifies visibility.
- Q: How can healthcare organizations learn more or request a demo?
- Visit Calantic and click “Enquire Now” for a personalized demonstration of the Calantic AI platform and DeepVessel FFR.
About DEEPVESSEL FFR
DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). The software processes coronary CTA images semi-automatically, generates a three-dimensional model of the coronary artery tree, and estimates CT FFR values. DEEPVESSEL FFR is FDA-Cleared, CE-Marked, NMPA-Cleared, HSA-Certified.
About Keya Medical
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers of excellence in Beijing, Shanghai, Shenzhen, and Seattle. Follow us on LinkedIn, Twitter, and Facebook.
Media Contact
contact@keyamedna.com
Learn more about DEEPVESSEL FFR
We are actively looking for clinical partners in the United States and EMEA.